L-368,899
Based on 8 publication(s) in Google Scholar
L-368,899 is an orally active and selective OT (oxytocin ) receptor antagonist, with IC50s of 8.9 and 26 nM for uterus of rat and human, respectively. L-368,899 can cross the blood-brain barrier (BBB). L-368,899 inhibits oxytocin-stimulated uterine contractions in rats and can be used in study of preterm labor.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 148927-60-0
- Formule: C26H42N4O5S2
- Masse moléculaire:554.77
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) L-368,899
More- Cell. 2025 Jun 26;188(13):3530-3549.e24. [Abstract]
- Research (Wash D C). 2025 Dec 16.
- J Headache Pain. 2025 Aug 6;26(1):179. [Abstract]
- Commun Biol. 2026 Apr 23;9(1):870. [Abstract]
- Front Pharmacol. 2019 Nov 15;10:1380. [Abstract]
- Mater Technol (N Y N Y). 2025 Jun 17.
- Neurosci Res. 2021 Jul:168:41-53. [Abstract]
- bioRxiv. 2024 May 14.
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
In Vivo Efficacy Study
-
Bio/Physico-chemical Assay
Activité biologique
IC50: 8.9 nM (rat uterus), 26 nM (human uterus)[3].
L-368,899 (3, 10, 30 mg/kg; i.d.; single) inhibits the contractile effects of OT (AD50= 7 mg/kg) with a long (>4 h) duration of action in vivo (AD50: the dose of L-368,899 required to reduce the response to OT by 50%)[1].
L-368,899 (10 mg/kg, p.o.; single) shows bioavailability (AUC 0-6 h) of 35%[1].
L-368,899 (0.54, 1.8, 5.4 mg/kg; i.v.; single) reduces both oxytocin-induced and endogenous increases in plasma PGFM concentration[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Adult female Sprague-Dawley rats (250-350 g)[1].
-
Dosage:0.1, 0.3, 1 mg/kg
-
Administration:Infused intravenous injection; single.
-
Result:Inhibited OT-stimulated uterine contractions with an AD50 value of 0.35 mg/kg.
-
Animal Model:Adult female Sprague-Dawley rats (250-350 g)[1].
-
Dosage:3, 10, 30 mg/kg
-
Administration:Intraduodenal; single.
-
Result:Exhibited a antagonism of OT-stimulated uterine contractions with an AD50 of 7 mg/kg and duration of action more than 4 h.
-
Animal Model:Adult female Sprague-Dawley rats (250-350 g)[1].
-
Dosage:10 mg/kg
-
Administration:Oral administration, single.
-
Result:Showed orally active with bioavailability (AUC 0-6 h) of 35%.
-
Animal Model:Mature Dorset cross ewes (53-57 kg; Removal of ovaries)[2].
-
Dosage:0.54, 1.8, 5.4 mg/kg (3, 10 and 30 µg/kg/min for 3 h; dissolved in 0.9% saline).
-
Administration:Intravenous infusion; single.
-
Result:Led to a significant decrease in both the frequency (from 2.2 to 1.0 episodes/ewe) and amplitude (from 68.8 to 31.8 pg/mL) of episodes of increased plasma concentration of PGFM.
Chemical Information
-
CAS No. 148927-60-0
-
Masse moléculaire 554.77
-
Formule C26H42N4O5S2
-
SMILES
O=S(C[C@]12[C@H](C[C@@H](CC2)C1(C)C)NC([C@@H](N)CCS(C)(=O)=O)=O)(N3CCN(C4=C(C=CC=C4)C)CC3)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
Cell
2025 Jun 26;188(13):3530-3549.e24. PMID: 40398420
L-368,899 purchased from MedChemExpress. Usage Cited in: Cell. 2025 Jun 26;188(13):3530-3549.e24. [Abstract]
L-368,899 hydrochloride (Oxtr antagonist) (10 mg/kg; i.p.; 20 min) treatment abolished the increased rebound activity of mPFCCacna1h+ neurons in estrus female mice induced by oxytocin.
-
L-368,899 purchased from MedChemExpress. Usage Cited in: Research (Wash D C). 2025 Dec 16.
Local application of the OXT receptor antagonist L-368,899 hydrochloride (1.25 mM; 500 nL per hemisphere) significantly reduced the peak Ca2+ activity of CCK neurons in CCK-Cre mice during initial interactions with a familiar mouse.
-
J Headache Pain
Compromised PGF2α signaling in the paraventricular hypothalamic nucleus contributes to the central sensitization of the nitroglycerin-induced chronic migraine in male mice. [Abstract]2025 Aug 6;26(1):179. PMID: 40770605 -
Commun Biol
Medial prefrontal cortex neurons integrate amygdala and hypothalamic oxytocin signals to mediate stress-induced social alterations. [Abstract]2026 Apr 23;9(1):870. PMID: 42026195 -
Front Pharmacol
Intradermal Injection of Oxytocin Aggravates Chloroquine-Induced Itch Responses via Activating the Vasopressin-1a Receptor/Nitric Oxide Pathway in Mice. [Abstract]2019 Nov 15;10:1380. PMID: 31824317 -
-
Neurosci Res
Oxytocin antagonist induced visceral pain and corticotropin-releasing hormone neuronal activation in the central nucleus of the amygdala during colorectal distention in mice. [Abstract]2021 Jul:168:41-53. PMID: 33932549
L-368,899 purchased from MedChemExpress. Usage Cited in: Neurosci Res. 2021 Jul:168:41-53. [Abstract]
Oxytocin antagonist L-368,899 hydrochloride (10 mg/kg; i.p.; 10 min) significantly increased the amplitudes of the VMR in C57BL/6J mice to graded CRD atall pressures compared with saline.
L-368,899 purchased from MedChemExpress. Usage Cited in: Neurosci Res. 2021 Jul:168:41-53. [Abstract]
Oxytocin antagonist L-368,899 hydrochloride (10 mg/kg; i.p.; 10 min) significantly decreased the percentage of timespent and distance of C57BL/6J mice in open arms.
L-368,899 purchased from MedChemExpress. Usage Cited in: Neurosci Res. 2021 Jul:168:41-53. [Abstract]
Oxytocin antagonist L-368,899 hydrochloride (10 mg/kg; i.p.; 10 min) significantly upregulated c-Fos-positive cells and c-Fos positive cells colocalized with CRH positive cells in the central amygdala (CeA) of C57BL/6J mice.
-
Pureté et documentation
Références
[2]. Mann GE, et al. Attenuation of PGF2alpha release in ewes infused with the oxytocin antagonist L-368,899. Domest Anim Endocrinol. 2003 Oct;25(3):255-62. [Content Brief]
[3]. Williams PD, et al. 1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility fo [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)